Alzheimer’s Trials Offer Few Answers for Investors, Patients
Shares of two big biotech stocks are plunging
CAT scan of Alzheimer's disease.
Photograph: Getty ImagesThis article is for subscribers only.
Data from two of the leading companies developing Alzheimer’s drugs left patients, researchers and investors with a frustrating message: keep waiting.
Trial results released Wednesday on two experimental drugs didn’t deliver a definitive answer as to whether the medications will work. Eli Lilly & Co.’s trial showed that patients who had been taking its drug longer did better on a cognitive test than those who hadn’t. Biogen Inc. reported data that further muddied the question of what dose of its drug is most effective.